Is BLTE or BNTX more profitable?

Belite Bio has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -13.14% -12.88% BioNTech -44.39% -5.30% -4.62%

Is INSM or BLTE more profitable?

Belite Bio has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Belite Bio's return on equity of -13.14% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% Belite Bio N/A -13.14% -12.88%

Is BLTE or VTRS more profitable?

Belite Bio has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -13.14% -12.88% Viatris -2.04% 19.04% 7.62%

Which has preferable earnings & valuation, BLTE or GMAB?

Genmab A/S has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Belite Bio N/A N/A -$77.61M -$2.53 N/A Genmab A/S $3.72B 4.78 $963M $1.32 21.60

Is BLTE or GMAB more profitable?

Genmab A/S has a net margin of 21.05% compared to Belite Bio's net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -13.14% -12.88% Genmab A/S 21.05% 15.34% 8.94%

Belite Bio (BLTE) Competitors

$146.63 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$145.32 -1.31 (-0.89%)

As of 07/2/2026 05:39 PM Eastern

Compare

BLTE vs. BNTX, INSM, VTRS, GMAB, and ASND

Should you buy Belite Bio stock or one of its competitors? MarketBeat compares Belite Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Belite Bio include BioNTech (BNTX), Insmed (INSM), Viatris (VTRS), Genmab A/S (GMAB), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.

How does Belite Bio compare to BioNTech?

Belite Bio (NASDAQ:BLTE) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Belite Bio has higher earnings, but lower revenue than BioNTech. Belite Bio is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
BioNTech	$3.25B	7.60	-$1.29B	-$5.88	N/A

In the previous week, BioNTech had 4 more articles in the media than Belite Bio. MarketBeat recorded 4 mentions for BioNTech and 0 mentions for Belite Bio. BioNTech's average media sentiment score of 0.89 beat Belite Bio's score of 0.00 indicating that BioNTech is being referred to more favorably in the news media.

Company	Overall Sentiment
Belite Bio	Neutral
BioNTech	Positive

Belite Bio has a beta of -1.23, indicating that its share price is 223% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Belite Bio has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
BioNTech	-44.39%	-5.30%	-4.62%

Belite Bio currently has a consensus price target of $203.00, indicating a potential upside of 38.44%. BioNTech has a consensus price target of $129.56, indicating a potential upside of 32.83%. Given Belite Bio's higher possible upside, equities research analysts clearly believe Belite Bio is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Summary

BioNTech beats Belite Bio on 12 of the 16 factors compared between the two stocks.

How does Belite Bio compare to Insmed?

Insmed (NASDAQ:INSM) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Insmed has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, meaning that its stock price is 223% less volatile than the broader market.

Belite Bio has lower revenue, but higher earnings than Insmed. Belite Bio is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	39.89	-$1.28B	-$5.75	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

In the previous week, Insmed had 7 more articles in the media than Belite Bio. MarketBeat recorded 7 mentions for Insmed and 0 mentions for Belite Bio. Insmed's average media sentiment score of 1.36 beat Belite Bio's score of 0.00 indicating that Insmed is being referred to more favorably in the media.

Company	Overall Sentiment
Insmed	Positive
Belite Bio	Neutral

0.5% of Belite Bio shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Belite Bio has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Belite Bio's return on equity of -13.14% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Belite Bio	N/A	-13.14%	-12.88%

Insmed presently has a consensus price target of $211.86, indicating a potential upside of 89.84%. Belite Bio has a consensus price target of $203.00, indicating a potential upside of 38.44%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Insmed beats Belite Bio on 9 of the 16 factors compared between the two stocks.

How does Belite Bio compare to Viatris?

Belite Bio (NASDAQ:BLTE) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Belite Bio has a beta of -1.23, suggesting that its stock price is 223% less volatile than the broader market. Comparatively, Viatris has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

Belite Bio has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
Viatris	-2.04%	19.04%	7.62%

Belite Bio has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Belite Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
Viatris	$14.30B	1.36	-$3.51B	-$0.26	N/A

Belite Bio currently has a consensus price target of $203.00, suggesting a potential upside of 38.44%. Viatris has a consensus price target of $17.50, suggesting a potential upside of 4.79%. Given Belite Bio's stronger consensus rating and higher possible upside, analysts plainly believe Belite Bio is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 0.3% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Viatris had 4 more articles in the media than Belite Bio. MarketBeat recorded 4 mentions for Viatris and 0 mentions for Belite Bio. Viatris' average media sentiment score of 0.72 beat Belite Bio's score of 0.00 indicating that Viatris is being referred to more favorably in the news media.

Company	Overall Sentiment
Belite Bio	Neutral
Viatris	Positive

Summary

Viatris beats Belite Bio on 8 of the 15 factors compared between the two stocks.

How does Belite Bio compare to Genmab A/S?

Belite Bio (NASDAQ:BLTE) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Belite Bio presently has a consensus price target of $203.00, indicating a potential upside of 38.44%. Genmab A/S has a consensus price target of $38.21, indicating a potential upside of 34.04%. Given Belite Bio's higher possible upside, equities analysts plainly believe Belite Bio is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Genmab A/S has a net margin of 21.05% compared to Belite Bio's net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
Genmab A/S	21.05%	15.34%	8.94%

Genmab A/S has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
Genmab A/S	$3.72B	4.78	$963M	$1.32	21.60

Belite Bio has a beta of -1.23, meaning that its share price is 223% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

In the previous week, Genmab A/S had 5 more articles in the media than Belite Bio. MarketBeat recorded 5 mentions for Genmab A/S and 0 mentions for Belite Bio. Genmab A/S's average media sentiment score of 0.69 beat Belite Bio's score of 0.00 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Overall Sentiment
Belite Bio	Neutral
Genmab A/S	Positive

Summary

Genmab A/S beats Belite Bio on 14 of the 16 factors compared between the two stocks.

How does Belite Bio compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Belite Bio has lower revenue, but higher earnings than Ascendis Pharma A/S. Belite Bio is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	21.02	-$258M	$8.67	31.66
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

0.5% of Belite Bio shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ascendis Pharma A/S has a net margin of 57.87% compared to Belite Bio's net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Belite Bio	N/A	-13.14%	-12.88%

Ascendis Pharma A/S currently has a consensus price target of $295.39, indicating a potential upside of 7.61%. Belite Bio has a consensus price target of $203.00, indicating a potential upside of 38.44%. Given Belite Bio's higher probable upside, analysts clearly believe Belite Bio is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Ascendis Pharma A/S has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, meaning that its stock price is 223% less volatile than the broader market.

In the previous week, Ascendis Pharma A/S had 9 more articles in the media than Belite Bio. MarketBeat recorded 9 mentions for Ascendis Pharma A/S and 0 mentions for Belite Bio. Ascendis Pharma A/S's average media sentiment score of 0.54 beat Belite Bio's score of 0.00 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Overall Sentiment
Ascendis Pharma A/S	Positive
Belite Bio	Neutral

Summary

Ascendis Pharma A/S beats Belite Bio on 13 of the 16 factors compared between the two stocks.

Get Belite Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLTE vs. The Competition

Export

Metric	Belite Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.88B	$3.78B	$7.18B	$12.47B
Dividend Yield	N/A	2.16%	2.67%	6.51%
P/E Ratio	-57.96	21.61	28.02	24.70
Price / Sales	N/A	325.99	534.82	99.69
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	7.14	8.66	10.96	6.46
Net Income	-$77.61M	$23.81M	$3.57B	$337.01M
7 Day Performance	-1.41%	3.39%	2.12%	1.69%
1 Month Performance	2.29%	10.81%	5.25%	3.81%
1 Year Performance	145.45%	62.61%	33.29%	23.90%

Belite Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLTE Belite Bio	2.8131 of 5 stars	$146.63 flat	$203.00 +38.4%	+145.4%	$5.88B	N/A	N/A	10
BNTX BioNTech	3.8178 of 5 stars	$93.74 -0.5%	$129.56 +38.2%	-11.0%	$23.72B	$2.81B	N/A	7,807	News Coverage Gap Down
INSM Insmed	3.6725 of 5 stars	$107.46 +2.6%	$211.86 +97.2%	+13.3%	$23.28B	$606.42M	N/A	1,664	Positive News Gap Down
VTRS Viatris	2.7838 of 5 stars	$15.97 -1.6%	$17.50 +9.6%	+80.5%	$18.59B	$14.56B	N/A	30,000	Gap Down
GMAB Genmab A/S	4.7837 of 5 stars	$27.58 +6.0%	$37.93 +37.5%	+39.7%	$17.19B	$3.90B	20.89	3,029	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLTE) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Belite Bio (BLTE) Competitors